HC Wainwright Expects Increased Earnings for FibroBiologics

FibroBiologics, Inc. (NASDAQ:FBLG) – Equities researchers at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for FibroBiologics in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.44) per share for the year, up from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.76) EPS.

FibroBiologics (NASDAQ:FBLG) last released its earnings results on Monday, March 31st. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01.

A number of other research firms have also recently commented on FBLG. Rodman & Renshaw initiated coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price target for the company. D. Boral Capital reissued a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a research note on Tuesday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $13.00.

FibroBiologics Stock Up 8.9 %

NASDAQ FBLG opened at $0.94 on Thursday. FibroBiologics has a 52 week low of $0.86 and a 52 week high of $13.59. The company has a fifty day moving average of $1.26 and a two-hundred day moving average of $2.13.

Institutional Trading of FibroBiologics

A number of large investors have recently made changes to their positions in FBLG. Charles Schwab Investment Management Inc. increased its stake in FibroBiologics by 5.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after buying an additional 3,451 shares during the period. The Manufacturers Life Insurance Company bought a new position in FibroBiologics in the 3rd quarter worth about $32,000. State Street Corp increased its position in shares of FibroBiologics by 26.5% during the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after acquiring an additional 99,789 shares during the period. Jane Street Group LLC bought a new position in FibroBiologics in the third quarter worth approximately $37,000. Finally, Barclays PLC lifted its holdings in shares of FibroBiologics by 363.2% in the 3rd quarter. Barclays PLC now owns 39,958 shares of the company’s stock worth $123,000 after buying an additional 31,331 shares during the period.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.